



Universiteit  
Leiden  
The Netherlands

## **Applications of the tumor-stroma ratio: Towards clinical implementation**

Pelt, G.W. van

### **Citation**

Pelt, G. W. van. (2020, September 30). *Applications of the tumor-stroma ratio: Towards clinical implementation*. Retrieved from <https://hdl.handle.net/1887/136913>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/136913>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden




The handle <http://hdl.handle.net/1887/136913> holds various files of this Leiden University dissertation.

**Author:** Pelt, G.W. van


**Title:** Applications of the tumor-stroma ratio: Towards clinical implementation

**Issue date:** 2020-09-30



# CHAPTER 1

General introduction and thesis outline



The tumor-node-metastasis (TNM) classification of the American Joint Committee on Cancer (AJCC) provides prognostic information and aids in clinical decision making<sup>1-3</sup>. It is developed to define the anatomical extent of tumor spread, making epidemiological studies comparable, and is commonly used for clinical decision making since it has prognostic impact. However, it's becoming more evident that additional prognostic factors are needed<sup>4</sup>. For example, 5-25% of stage II colorectal cancer patients will develop recurrence of disease within 5 years. In addition, patients with stage IIB have a worse prognosis compared to stage IIIA colorectal cancer patients, which could lead to undertreatment (stage II) or overtreatment (stage III)<sup>5</sup>. Previously proposed additional biomarkers have been based on tumor cell characteristics, like tumor cell morphology, molecular pathways, gene expression and the tumor immune response<sup>6-8</sup>. A disadvantage of some of these is the high costs of generating genetic and transcriptomic data.

After years of focusing on the malignant cells to understand the role of tumor suppressors and oncogenic factors in the transformation to malignancy, nowadays the so-called tumor microenvironment (TME) is subject of investigation as well. It is increasingly known that the malignant cell relies on this stromal part of the tumor and therefore does not act alone. Intratumoral stroma within the TME is variable and different cell-types like infiltrating immune cells, cancer-associated fibroblasts, endothelial cells and pericytes all play a role in supporting malignant transformation, invasion of the tumor and metastasis<sup>9-10</sup>. Moreover, intratumoral stroma has been associated with reduced chemotherapy delivery<sup>11</sup> and increased chemotherapy resistance<sup>12</sup>, and consequently could play a role in patient treatment outcome.

A prognostic biomarker based on the TME is the tumor-stroma ratio (TSR), which is the main subject of this thesis. This biomarker is based on microscopic pathological analysis on conventional hematoxylin and eosin (H&E)-stained paraffin sections and assessment is fast, cheap and reliable. It has been shown to link patients with a high stromal content to worse prognosis. Since 2007, when Mesker et al. first published the TSR to be of prognostic value for survival of stage I-III colon cancer patients, many studies have validated this finding in different types of epithelial cancer<sup>13-32</sup>.

An extensive literature overview on the background of tumor stroma and the tumor-stroma ratio is given in **Chapter 2**, followed by a detailed description of the assessment of the tumor-stroma ratio in **Chapter 3**, including possible pitfalls and recommendations.

Metastatic lymph nodes have important prognostic implications. In colorectal cancer, lymph node-negative patients have a more than 20% higher survival rate after 5 years compared to lymph node-positive patients <sup>5</sup>. Furthermore, research has shown that not only the number of positive lymph nodes is important for patient outcome, but also the composition of the microenvironment within the lymph node metastasis <sup>33</sup>. In **Chapter 4** we evaluated the TSR in metastatic lymph nodes of stage III colon cancer patients to investigate the possible additional prognostic value. Moreover, it was of interest whether the TSR in the lymph nodes was associated with the TSR in the primary tumor. These same research questions have also been investigated within a cohort of primary breast cancer patients. In **Chapter 5** the results of these studies on the prognostic importance of the TSR in metastatic lymph nodes have been summarized.

The search for prognostic and predictive biomarkers for implementation in routine clinical diagnostics has already resulted in several biomarkers which nowadays are used in the clinic to characterize colorectal tumors and determine specific treatment. Amongst them are the microsatellite instability (MSI) status and mutations in *BRAF* and *KRAS*. MSI status is the most consistently used biomarker for colorectal cancer prognosis in clinical practice, whereas *BRAF* and *KRAS* mutations are primarily used in the metastatic setting. However, in general, colorectal cancer patients are being treated in the adjuvant setting regardless of clinical or molecular characteristics, with heterogenous response to treatment. Patients with a *BRAF* mutation are known to have a poor prognosis and to not respond well to standard chemotherapy or *BRAF* targeted therapy <sup>34, 35</sup>. Studies showed the existence of different colorectal cancer subtypes <sup>6</sup>, and even more specifically, two *BRAF* mutant subtypes <sup>36</sup>. Hence, the need for understanding the biology of *BRAF* mutated colorectal cancer and recognizing the different subtypes to select the most effective treatment for these patients. Unfortunately, most of the methods to detect these subtypes are based on gene expression arrays, which are, as stated before, difficult and expensive to implement clinically, whereas the TSR is easier to implement with little additional costs. Therefore, as described in **Chapter 6**, we investigated whether the TSR in combination with the *BRAF* mutation status could select for a subgroup of patients who might need a different treatment approach.

Due to changes in the tissue composition induced by neoadjuvant chemo- and/or radiotherapy, patients who are treated prior to surgery need to be excluded for TSR scoring <sup>37-40</sup>. As a consequence, rectal cancer and esophageal cancer patients, who often receive neoadjuvant therapy, are usually excluded from TSR studies. Analyzing the TSR in biopsies to predict the

prognosis of the patient might be an alternative, although the TSR cannot be determined at the most invasive front. However, in esophageal cancer, for instance, it has been shown that the TSR score assessed on biopsies could still be used as an independent prognostic factor for survival<sup>41</sup>. Especially for stroma-high cases it might be of interest to use the TSR as prognosticator, as the correlation between biopsies and primary tumors was found to be 100%. Another highly interesting approach to use the TSR in biopsies, is to see if it could aid in the prediction of the response to neoadjuvant treatment. This might prevent unnecessary neoadjuvant therapy for patients who are likely not to respond well to the treatment and therefore could continue directly with resection. This potential use of the TSR was investigated in both rectal cancer (**Chapter 7**) as well as in esophageal cancer (**Chapter 8**) patients.

Finally, the research published in this thesis is summarized and discussed in **Chapter 9**. The future perspectives on how to continue this line of research towards implementation for patient care are described here as well. **Chapter 10** describes the summary, discussion and future perspectives in Dutch.

## References

1. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. *Cancer* 1997; 9: 1803-1804
2. Sobin LH, Hermanek P, Hutter RV. TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. *Cancer* 1988; 11: 2310-2314
3. Locker GY, Hamilton S, Harris J *et al.* ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J Clin Oncol* 2006; 33: 5313-5327
4. Lea D, Haland S, Hagland HR, Soreide K. Accuracy of TNM staging in colorectal cancer: a review of current culprits, the modern role of morphology and stepping-stones for improvements in the molecular era. *Scand J Gastroenterol* 2014; 10: 1153-1163
5. Gao P, Song YX, Wang ZN *et al.* Is the prediction of prognosis not improved by the seventh edition of the TNM classification for colorectal cancer? Analysis of the surveillance, epidemiology, and end results (SEER) database. *BMC Cancer* 2013; 123
6. Guinney J, Dienstmann R, Wang X *et al.* The consensus molecular subtypes of colorectal cancer. *Nat Med* 2015; 11: 1350-1356
7. Galon J, Mlecnik B, Bindea G *et al.* Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. *J Pathol* 2014; 2: 199-209
8. Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer--ready for diagnostic practice? *Hum Pathol* 2016; 1: 4-19
9. Bremnes RM, Donnem T, Al-Saad S *et al.* The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. *J Thorac Oncol* 2011; 1: 209-217
10. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. *Cancer Cell* 2012; 3: 309-322
11. Provenzano PP, Cuevas C, Chang AE *et al.* Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. *Cancer Cell* 2012; 3: 418-429
12. Hale MD, Hayden JD, Grabsch HI. Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response. *Cell Oncol (Dordr)* 2013; 2: 95-112
13. Mesker WE, Junggeburst JM, Szuhai K *et al.* The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. *Cell Oncol* 2007; 5: 387-398
14. Huijbers A, Tollenaar RA, van Pelt GW *et al.* The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. *Ann Oncol* 2013; 1: 179-185
15. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. *Ann Oncol* 2014; 3: 644-651
16. West NP, Dattani M, McShane P *et al.* The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. *Br J Cancer* 2010; 10: 1519-1523

17. Courrech Staal EF, Wouters MW, van Sandick JW *et al.* The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? *Eur J Cancer* 2010; 4: 720-728
18. de Kruijf EM, van Nes JG, van de Velde CJ *et al.* Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. *Breast Cancer Research & Treatment* 2011; 3: 687-696
19. Dekker TJ, van de Velde CJ, van Pelt GW *et al.* Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). *Breast Cancer Res Treat* 2013; 2: 371-379
20. Gujam FJ, Edwards J, Mohammed ZM, Going JJ, McMillan DC. The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. *Br J Cancer* 2014; 1: 157-165
21. Liu J, Liu J, Li J *et al.* Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma. *Gynecol Oncol* 2014; 1: 81-86
22. Lv Z, Cai X, Weng X *et al.* Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation. *Surgery* 2015; 1: 142-150
23. Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA. The prognostic value of tumour-stroma ratio in triple-negative breast cancer. *Eur J Surg Oncol* 2012; 4: 307-313
24. Wang K, Ma W, Wang J *et al.* Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. *J Thorac Oncol* 2012; 9: 1457-1461
25. Zhang T, Xu J, Shen H *et al.* Tumor-stroma ratio is an independent predictor for survival in NSCLC. *International Journal of Clinical & Experimental Pathology* 2015; 9: 11348-11355
26. Pongsuvareeyakul T, Khunamornpong S, Settakorn J *et al.* Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery. *Asian Pac J Cancer Prev* 2015; 10: 4363-4368
27. Zhang XL, Jiang C, Zhang ZX *et al.* The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer. *Oncol Res Treat* 2014; 9: 480-484
28. Almagush A, Heikkinen I, Bakhti N *et al.* Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers. *Histopathology* 2018; 7: 1128-1135
29. Eriksen AC, Sorensen FB, Lindebjerg J *et al.* The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. *Int J Colorectal Dis* 2018; 8: 1115-1124
30. Karpathiou G, Vieville M, Gavid M *et al.* Prognostic significance of tumor budding, tumor-stroma ratio, cell nests size, and stroma type in laryngeal and pharyngeal squamous cell carcinomas. *Head & Neck* 2019; 6: 1918-1927
31. Zengin M. Tumour Budding and Tumour Stroma Ratio are Reliable Predictors for Death and Recurrence in Elderly Stage I Colon Cancer Patients. *Pathology, Research & Practice* 2019; 11: 152635
32. Zou MX, Zheng BW, Liu FS *et al.* The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma. *Neurosurgery* 2019;

33. Del Pozo Martin Y, Park D, Ramachandran A *et al.* Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization. *Cell Rep* 2015; 11: 2456-2469
34. Corcoran RB, Andre T, Atreya CE *et al.* Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer. *Cancer Discov* 2018; 4: 428-443
35. Hong DS, Morris VK, El Osta B *et al.* Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. *Cancer Discov* 2016; 12: 1352-1365
36. Barras D, Missiaglia E, Wirapati P *et al.* BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. *Clin Cancer Res* 2017; 1: 104-115
37. Aktepe F, Kapucuoglu N, Pak I. The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. *Histopathology* 1996; 1: 63-67
38. McCluggage WG, Lyness RW, Atkinson RJ *et al.* Morphological effects of chemotherapy on ovarian carcinoma. *J Clin Pathol* 2002; 1: 27-31
39. Nagtegaal I, Gaspar C, Marijnen C *et al.* Morphological changes in tumour type after radiotherapy are accompanied by changes in gene expression profile but not in clinical behaviour. *J Pathol* 2004; 2: 183-192
40. Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. *Lancet Oncol* 2003; 9: 529-536
41. Courrech Staal EF, Smit VT, van Velthuysen ML *et al.* Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies. *Eur J Cancer* 2011; 3: 375-382